TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20002624

Group type: EXPERIMENTAL
Intervention: Individualized dietary and lifestyle counselling
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1062
Study: 18698545

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (no statin)
Number of subjects: 78
Study: 15597181

Group type: EXPERIMENTAL
Intervention: Speeded manual choice reaction time (RT) task
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cued visual target report from a masked display
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Task order manipulation (reversed order of tasks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cued location of the target
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Number of target features to be reported
Number of subjects: 0
Study: 14660913

Group type: EXPERIMENTAL
Intervention: Topical ciprofloxacin/dexamethasone
Number of subjects: 201

Group type: COMPARATOR
Intervention: Ciprofloxacin alone
Number of subjects: 201
Study: 10227630

Group type: COMPARATOR
Intervention: 25 microg/kg BDNF for 9 months
Number of subjects: 1135

Group type: COMPARATOR
Intervention: 100 microg/kg BDNF for 9 months
Number of subjects: 1135

Group type: COMPARATOR
Intervention: 100 microg/kg BDNF for 9 months (BDNF 'responders')
Number of subjects: 1135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1135
Study: 8063466

Group type: EXPERIMENTAL
Intervention: L-carnitine (LC) group, 2 grams L-carnitine in a citrus drink twice daily for 7 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (PL) group, citrus drink only for 7 days
Number of subjects: 20
Study: 2522729

Group type: EXPERIMENTAL
Intervention: Doxazosin (1 to 8 mg/day)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Atenolol (50 to 100 mg/day)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 5072236

Group type: EXPERIMENTAL
Intervention: Level 1 task difficulty (light signals only)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Level 2 task difficulty (light signals with driving simulator film)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Level 3 task difficulty (conflicting light signals with driving simulator film)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Heart rate across task levels
Number of subjects: 15
Study: 30895824

Group type: EXPERIMENTAL
Intervention: Liuzijue Qigong (LQG) training method with 6 monosyllabic speech sounds
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional voice training (abdominal breathing and yawn‐sign exercises)
Number of subjects: 48
Study: 28321881

Group type: EXPERIMENTAL
Intervention: Heavier load (HL; 80% MVIT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lighter load (LL; 30% MVIT)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Forced repetition (FR)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Breakdown set (BD)
Number of subjects: 8
Study: 24373610

Group type: EXPERIMENTAL
Intervention: Aspirin (81mg/day) for 7 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fish Oil (FO) (4g/day) for 28 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of Aspirin and Fish Oil for 7 days
Number of subjects: 30
Study: 22435509

Group type: EXPERIMENTAL
Intervention: Sequential therapy (lansoprazole, amoxicillin, clarithromycin, and metronidazole)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Concomitant therapy (lansoprazole, amoxicillin, clarithromycin, and metronidazole)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Sequential therapy
Number of subjects: 169

Group type: COMPARATOR
Intervention: Concomitant therapy
Number of subjects: 169
Study: 19912138

Group type: EXPERIMENTAL
Intervention: Skin-to-skin care
Number of subjects: 137

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 137
Study: 18686631

Group type: EXPERIMENTAL
Intervention: Enteral Nutrition (EN)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Parenteral Nutrition (PN)
Number of subjects: 41
Study: 16118546

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 63

Group type: COMPARATOR
Intervention: Unfractionated heparin plus eptifibatide
Number of subjects: 63
Study: 14519753

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 3385
Study: 10754950

Group type: EXPERIMENTAL
Intervention: 1% benzalkonium chloride vaginal suppository and neonatal bath
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo vaginal suppository and neonatal bath
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 1% benzalkonium chloride
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 8965890

Group type: EXPERIMENTAL
Intervention: Pamidronate (90 mg, two-hour intravenous infusion monthly for 12 cycles)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study: 1582586

Group type: EXPERIMENTAL
Intervention: Injection of ethanolamine oleate and thrombin
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 38
Study: 4051527

Group type: EXPERIMENTAL
Intervention: Sunscreen application (various brands)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Two specific sunscreens
Number of subjects: 50
Study: 31537221

Group type: EXPERIMENTAL
Intervention: Post-pyloric feeding
Number of subjects: 175

Group type: COMPARATOR
Intervention: Gastric feeding
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Bronchoscope treatment
Number of subjects: 175
Study: 30064517

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) bolus of tranexamic acid (TXA) peri-operatively plus oral TXA post-operatively for 24 hours
Number of subjects: 1166

Group type: EXPERIMENTAL
Intervention: Intravenous (IV) bolus of TXA peri-operatively
Number of subjects: 1166

Group type: COMPARATOR
Intervention: Standard care (no TXA)
Number of subjects: 1166
Study: 26329313

Group type: EXPERIMENTAL
Intervention: Propofol-ketamine combination (GroupPK, n: 48)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Propofol (GroupP, n: 47)
Number of subjects: 95
Study: 24569158

Group type: EXPERIMENTAL
Intervention: Adapted hypertension self-management interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Established hypertension self-management interventions
Number of subjects: 0
Study: 22759721

Group type: EXPERIMENTAL
Intervention: Any NSAID
Number of subjects: 4735

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4735

Group type: EXPERIMENTAL
Intervention: Non-aspirin NSAIDs
Number of subjects: 4735

Group type: EXPERIMENTAL
Intervention: Any NSAID (among men with no indications for NSAID use)
Number of subjects: 4735

Group type: EXPERIMENTAL
Intervention: Arthritis
Number of subjects: 4735

Group type: EXPERIMENTAL
Intervention: Other inflammation-related musculoskeletal conditions
Number of subjects: 4735

Group type: EXPERIMENTAL
Intervention: Headaches
Number of subjects: 4735
Study: 19535988

Group type: EXPERIMENTAL
Intervention: 0.15 mg kg(‐1) ketamine followed by a continuous infusion of 1.4 microg kg(‐1) min(‐1) over 24 h
Number of subjects: 37

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 0.15 mg kg(‐1) ketamine
Number of subjects: 37
Study: 17591127

Group type: EXPERIMENTAL
Intervention: Isoflurane sedation via AnaConDa
Number of subjects: 20

Group type: COMPARATOR
Intervention: Midazolam sedation (intravenous)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: End‐tidal isoflurane concentration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BIS XP
Number of subjects: 20
Study: 16327136

Group type: EXPERIMENTAL
Intervention: Music distraction
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 40
Study: 11888869

Group type: EXPERIMENTAL
Intervention: Completion lymph node dissection (CLND)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Positive SLNs detected by immunohistochemistry (IHC)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Positive SLNs detected by hematoxylin and eosin (H&E) staining
Number of subjects: 274
Study: 10343981

Group type: EXPERIMENTAL
Intervention: Immunosuppressive agents (cyclosporin A and methotrexate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Choleretic agents (ursodeoxycholic acid)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biliary tract reconstructive surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proctocolectomy for CUC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Orthotopic liver transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cupruretic agents
Number of subjects: 0
Study: 7769297

Group type: EXPERIMENTAL
Intervention: 15 micrograms of rHA0
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 15 micrograms of rHA0 plus alum
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: 90 micrograms of rHA0
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Licensed subvirion vaccine
Number of subjects: 127

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 127
Study: 1707337

Group type: EXPERIMENTAL
Intervention: Cronassial (100 mg) administered by intramuscular (IM) injection daily
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Vincristine (2.0 mg/m2 every other week by bolus injection followed by a 3-day continuous IV infusion)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dexamethasone (50 mg/d for 3 days weekly or every other week)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Electrophysiologic studies of peripheral nerve function
Number of subjects: 27
Study: 6805176

Group type: EXPERIMENTAL
Intervention: 0.25 ml polycomponent meningococcal vaccine
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 0.5 ml polycomponent meningococcal vaccine
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: 1.0 ml polycomponent meningococcal vaccine
Number of subjects: 168

Group type: COMPARATOR
Intervention: Placebo (0.5 ml physiological saline)
Number of subjects: 168
Study: 30951604

Group type: EXPERIMENTAL
Intervention: Person-centered physical therapy prehabilitation program
Number of subjects: 118

Group type: COMPARATOR
Intervention: Conventional preoperative care
Number of subjects: 118
Study: 28939648

Group type: EXPERIMENTAL
Intervention: Moderate-intensity continuous exercise (40% peak power output)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Higher-intensity interval exercise (70% peak power output)
Number of subjects: 22

Group type: COMPARATOR
Intervention: No-exercise control
Number of subjects: 22
Study: 26946925

Group type: EXPERIMENTAL
Intervention: Antibiotic-impregnated catheters
Number of subjects: 1485

Group type: EXPERIMENTAL
Intervention: Heparin-impregnated catheters
Number of subjects: 1485

Group type: COMPARATOR
Intervention: Standard central venous catheters
Number of subjects: 1485
Study: 25201152

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 22
Study: 22855633

Group type: EXPERIMENTAL
Intervention: Fever-range whole-body hyperthermia (FR-WBH)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (propofol sedation only)
Number of subjects: 18
Study: 21037443

Group type: EXPERIMENTAL
Intervention: Mechanical bowel preparation (MBP)
Number of subjects: 178
Study: 17890500

Group type: EXPERIMENTAL
Intervention: Large amount of food
Number of subjects: 28

Group type: COMPARATOR
Intervention: Small amount of food
Number of subjects: 28
Study: 16282291

Group type: EXPERIMENTAL
Intervention: Azithromycin (250 mg/day)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 12113567

Group type: EXPERIMENTAL
Intervention: Silicone intraocular lens (Sl‐‐30NB)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Acrylic intraocular lens (Acrysof MA60BM)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Silicone intraocular lens (Sl‐‐30NB) with concurrent ocular diseases
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Silicone intraocular lens (Sl‐‐30NB) without concurrent ocular diseases
Number of subjects: 80

Group type: COMPARATOR
Intervention: Acrylic intraocular lens (Acrysof MA60BM) with concurrent ocular diseases
Number of subjects: 80

Group type: COMPARATOR
Intervention: Acrylic intraocular lens (Acrysof MA60BM) without concurrent ocular diseases
Number of subjects: 80
Study: 10203311

Group type: EXPERIMENTAL
Intervention: Articulation (repeating a number aloud)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Counting backwards aloud in multiples of seven (articulation and attention)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Counting backwards silently (attention)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No mental task (neither articulation nor attention)
Number of subjects: 36
Study: 8525537

Group type: EXPERIMENTAL
Intervention: Intravenous ganciclovir (6 mg/kg once a day, Monday through Friday) for 4 or more weeks
Number of subjects: 51

Group type: COMPARATOR
Intervention: Less than 2 weeks of ganciclovir
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 6 or more weeks of ganciclovir
Number of subjects: 51
Study: 2239781

Group type: EXPERIMENTAL
Intervention: 80% CHO diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: 43% CHO diet
Number of subjects: 0
Study: 367238

Group type: EXPERIMENTAL
Intervention: Hyaluronidase admixed with local anesthetic
Number of subjects: 2

Group type: COMPARATOR
Intervention: No hyaluronidase
Number of subjects: 2
Study: 31185030

Group type: EXPERIMENTAL
Intervention: Real-time portable nanopore sequencing of virus isolates from clinical samples
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Phylogenetic analysis combined with CHIKV notified case numbers
Number of subjects: 11
Study: 28859326

Group type: EXPERIMENTAL
Intervention: COBRA-light (prednisolone and MTX)
Number of subjects: 162

Group type: COMPARATOR
Intervention: COBRA therapy (prednisolone, MTX and SSZ)
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: COBRA-light and COBRA therapy
Number of subjects: 162
Study: 25588594

Group type: EXPERIMENTAL
Intervention: Ropivacaine plus 0.5 µg.kg‐1 dexmedetomidine (group LD1)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ropivacaine plus 1 µg.kg‐1 dexmedetomidine (group LD2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Retrobulbar ropivacaine (group L)
Number of subjects: 90
Study: 23236956

Group type: EXPERIMENTAL
Intervention: BoNT‐A + mCIMT
Number of subjects: 34

Group type: COMPARATOR
Intervention: BoNT‐A + BOT
Number of subjects: 34
Study: 22136298

Group type: EXPERIMENTAL
Intervention: Enhanced Intervention (EI) group
Number of subjects: 1021

Group type: COMPARATOR
Intervention: Minimum Intervention (MI) group
Number of subjects: 1021

Group type: EXPERIMENTAL
Intervention: Both EI and MI groups
Number of subjects: 1021
Study: 18679829

Group type: EXPERIMENTAL
Intervention: Written educational information on cancer genetics
Number of subjects: 379

Group type: COMPARATOR
Intervention: No educational information
Number of subjects: 379
Study: 17328583

Group type: EXPERIMENTAL
Intervention: AZSR (extended-release microsphere formulation of azithromycin)
Number of subjects: 377

Group type: EXPERIMENTAL
Intervention: AZSR
Number of subjects: 377

Group type: COMPARATOR
Intervention: High-fat meal
Number of subjects: 377

Group type: COMPARATOR
Intervention: Standard meal
Number of subjects: 377

Group type: COMPARATOR
Intervention: AZSR with antacid
Number of subjects: 377
Study: 14968129

Group type: EXPERIMENTAL
Intervention: PROT- diet (15% protein, 54% CHO)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: PROT+ diet (19% protein, 50% CHO)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Both diets (PROT- and PROT+)
Number of subjects: 121
Study: 11965463

Group type: EXPERIMENTAL
Intervention: CO2 pneumoperitoneum (12 mmHg)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Abdominal wall retraction (6-10 kps)
Number of subjects: 34
Study: 9749496

Group type: EXPERIMENTAL
Intervention: Intense follow-up (Group B)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Conventional follow-up (Group A)
Number of subjects: 207
Study: 7524607

Group type: EXPERIMENTAL
Intervention: Mitozantrone (7-14 mg m-2), Methotrexate (35 mg m-2, max 50 mg), Mitomycin (7 mg m-2) with filgrastim (5 micrograms kg-1)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mitozantrone (7 mg m-2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mitozantrone (10 mg m-2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mitozantrone (12 mg m-2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mitozantrone (14 mg m-2)
Number of subjects: 24
Study: 2884788

Group type: EXPERIMENTAL
Intervention: H1-antihistamine preparation terfenadine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined administration of H1-antihistamine terfenadine and H2-antihistamine ranidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: H2-antihistamine preparation ranidine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30473186

Group type: EXPERIMENTAL
Intervention: Maternal RSV vaccination
Number of subjects: 6196

Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 6196
Study: 27498085

Group type: EXPERIMENTAL
Intervention: 38% H2O2 for 20min followed by ozone for 60s
Number of subjects: 26

Group type: COMPARATOR
Intervention: 38% H2O2 for 20min only (Control)
Number of subjects: 26
Study: 24928191

Group type: EXPERIMENTAL
Intervention: Spray and stretch
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Psychological factors
Number of subjects: 70
Study: 22607853

Group type: EXPERIMENTAL
Intervention: Cangrelor
Number of subjects: 10900

Group type: COMPARATOR
Intervention: Clopidogrel (standard of care)
Number of subjects: 10900
Study: 19914598

Group type: EXPERIMENTAL
Intervention: Alcohol at .25 g/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alcohol at .5 g/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alcohol at .75 g/kg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 18655556

Group type: EXPERIMENTAL
Intervention: Combined therapy with hypha cordyceps (0.33 g per capsule, 3 capsules per day) and ginkgo leaf tablet (0.23 g per tablet, 1 tablet per day) for 3 months
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 65
Study: 16192842

Group type: EXPERIMENTAL
Intervention: Rapid titration group (RTG) - Quetiapine 200 mg/day on day 1; 400 mg/day on day 2; 600 mg/day on day 3
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional titration group (CTG) - Quetiapine 50 mg/day on day 1; 100 mg/day on day 2; 200 mg/day on day 3; 300 mg/day on day 4; 400 mg/day on day 5
Number of subjects: 0
Study: 11875640

Group type: EXPERIMENTAL
Intervention: Alcohol (females 0.35 g/kg; males 0.45 g/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo drinks
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 28
Study: 10609199

Group type: EXPERIMENTAL
Intervention: Capsular bag fixation (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ciliary sulcus fixation (Group B)
Number of subjects: 20
Study: 7814785

Group type: COMPARATOR
Intervention: Normal subjects
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Hypertensive patients under age 60
Number of subjects: 70

Group type: COMPARATOR
Intervention: Normotensive subjects under age 60
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Subjects over age 60
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: QT/QS2 ratio changes
Number of subjects: 70
Study: 1793726

Group type: EXPERIMENTAL
Intervention: Zeniplatin at doses ranging from 8 to 145 mg/m2, given as a 60- to 90-min i.v. infusion every 3 weeks
Number of subjects: 46
Study: 7198436

Group type: EXPERIMENTAL
Intervention: Tympanometric screenings
Number of subjects: 288
Study: 31448513

Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/d; 3 weeks on/1 week off) plus letrozole (2.5 mg/d, continuous)
Number of subjects: 507

Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/d; 3 weeks on/1 week off) plus fulvestrant (500 mg)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Palbociclib plus fulvestrant
Number of subjects: 507
Study: 30793375

Group type: EXPERIMENTAL
Intervention: Live-action video (n = 755)
Number of subjects: 2261

Group type: EXPERIMENTAL
Intervention: Animated video (n = 753)
Number of subjects: 2261

Group type: COMPARATOR
Intervention: CDC wellness information (Control, n = 753)
Number of subjects: 2261

Group type: EXPERIMENTAL
Intervention: Live-action video
Number of subjects: 2261

Group type: EXPERIMENTAL
Intervention: Animated video
Number of subjects: 2261

Group type: COMPARATOR
Intervention: CDC text
Number of subjects: 2261
Study: 29258572

Group type: EXPERIMENTAL
Intervention: rosuvastatin/ticagrelor
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: rosuvastatin/clopidogrel
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: simvastatin plus ezetimibe/ticagrelor
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: simvastatin plus ezetimibe/clopidogrel
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: All therapies
Number of subjects: 300
Study: 26105004

Group type: EXPERIMENTAL
Intervention: In-hospital nursing intervention delivered by a trained nurse practitioner according to self-regulatory theory
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 82
Study: 24939519

Group type: EXPERIMENTAL
Intervention: Mindfulness meditation (MM) intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 34
Study: 22784653

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) for 5 sessions every other day
Number of subjects: 28

Group type: COMPARATOR
Intervention: CO(2) laser therapy
Number of subjects: 28
Study: 18829008

Group type: EXPERIMENTAL
Intervention: Weight loss surgery (bariatric surgery) resulting in >25% reduction of initial body weight
Number of subjects: 25
Study: 17967652

Group type: EXPERIMENTAL
Intervention: Buffered physiological saline
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Buffered hypertonic saline
Number of subjects: 80
Study: 15156249

Group type: EXPERIMENTAL
Intervention: Aescin + essential phospholipids (AEPL) topical gel
Number of subjects: 0